TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04170387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxometer
Description: Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxometer
Description: Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)
Study: NCT01756859

Intervention type: PROCEDURE
Intervention: MRI Scan
Study: NCT00647114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V930
Description: V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V932
Description: V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
Study: NCT03817073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iowa Oral Performance Instrument (IOPI)
Description: Using biofeedback to attain repetitions of 80% of baseline MIP.
Study: NCT03217032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YUVA-GT-F801
Description: Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
Study: NCT04625868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Patients will watch a preoperative educational video on proper opioid use and disposal.
Study: NCT02680743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education of parents to pursue prompt hearing screening.
Description: Parents of patients will be counseled on the risks of hearing loss with a positive screen.
Study: NCT00322946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN4delta30-4995
Description: Live attenuated rDEN4delta30-4995 vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN4delta30-4995
Description: Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
Study: NCT03381144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0334
Description: Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0334
Description: Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0334
Description: Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive GDC-0334-matching placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive GDC-0334-matching placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive GDC-0334-matching placebo.
Study: NCT01641029

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention
Study: NCT01048827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 1. 1250 uMol\*min (AUC to time 6 hrs)\^~2. 1400 uMol\*min (AUC to time 6 hrs~3. 1550 uMol\*min (AUC to time 6 hrs)\^
Study: NCT00982267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU014813
Description: Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
Study: NCT00621764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)
Description: ≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)
Description: 0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)
Description: ≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)
Description: 0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
Study: NCT04164264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: At T0, a propofol infusion at a rate of 1.5 mg/kg/min will be started until apnea is achieved. Loss of consciousness will be defined clinically using loss of eyelash reflex (TLOER) and tolerance of nasal cannulae (TNC), tested every 10 sec., and by a BIS \<60 for 30 sec. (TBIS). Apnea will be defined as absence of end-tidal CO2 for at least 20 seconds (TAPNEA). A saliva sample with be taken under anesthesia for genome-wide association study and principal component analysis.
Study: NCT05179564

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iohexol administration
Description: IV injection of weight-dependent low dose of iohexol at time 0

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iohexol blood sampling
Description: Blood sampling will be performed through an arterial (preferred) or venous line, other than the iohexol infusion line. In the first 30 minutes after iohexol injection, a blood sample of 2 ml will be obtained for iohexol concentration measurement and determination of renal biomarkers serum creatinine, cystatin C, betatrace protein. Subsequently, 2 up to 5 additional blood samples of 0,5 ml will be obtained for iohexol determination at 60,120 ,180, 240 and 360 minutes after iohexol injection to calculate iohexol plasma clearance from the plasma disappearance curve
Study: NCT00121485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist System (LVAS)
Description: Implantation of left ventricular assist device for hemodynamic support

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left Ventricular Assist System (LVAS)
Description: Implantation of left ventricular assist device for hemodynamic support
Study: NCT00659009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced barometric pressure
Description: Sleep in reduced barometric pressure environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sea level equivalent barometric pressure
Description: Sleep in barometric pressure equivalent to sea level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced barometric pressure
Description: Sleep in reduced barometric pressure environment.
Study: NCT02331927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.~compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression.
Study: NCT02306525

Intervention type: PROCEDURE
Intervention: Arthroscopic surgery of the hip joint
Description: Arthroscopic treatment of Femoroacetabular Impingement
Study: NCT00615420

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: manuka honey
Description: Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
Study: NCT03704233

Intervention type: PROCEDURE
Intervention: Transbronchial cryobiopsy
Description: Transbronchial cryobiopsy procedure
Study: NCT03883659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: patients with frozen shoulder in the smartphone group will use the smartphone to conduct the home exercise program. The patients will be asked to follow the description to have mobility assessment at least 1 week and do the individualized exercise themselves.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional paper hangouts
Description: patients with frozen shoulder in the smartphone group will use the paper hangouts to conduct the home exercise program. The content of the paper hangouts were description of the home exercise.
Study: NCT01673373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCAST™ Rx Stent System
Description: All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
Study: NCT01116661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevuline Acid (ALA)
Description: Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
Study: NCT00242658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity Intervention
Description: Tailored physical activity computer reports will be provided to patients and physicians.
Study: NCT03024151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comthyroid
Description: T4/T3 combination replacement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthroid
Description: T4 mono replacement
Study: NCT00470223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study: NCT03812198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 32731 modified release tablet
Description: At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 32731 blend, hard capsule
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 32731 API, hard capsule
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 32731 API, hard capsule
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 32731 soft capsule
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 32731 gastro-resistant capsule
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
Study: NCT02637531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).
Study: NCT01378247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Focused Nursing
Description: All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
Study: NCT01697605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Study: NCT01596985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation using the PlasmaJet system
Description: Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
Study: NCT00550030

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVB-311nm radiation
Description: UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: no UV exposure
Study: NCT03714828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of TVEC into target lesions - week 1-2
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of TVEC into target lesions 3wks after 1st injection
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the second and subsequent doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of TVEC into target lesions 2wks after 2nd injection
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of TVEC into target lesions 2wks after 3rd injection
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses.
Study: NCT04358055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WET® gel
Description: In each application, a puff should be administered in each nostril every two seconds, with minimal inspirations, up to a sensation of lubrication in the external conduct is perceived. Then the patient should proceed with short inspirations and light touching of ala of the nose, to favour the distribution of the gel. A maximum of 4 erogations (2/nostril) is allowed in each application session.
Study: NCT01333397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. (in the muscle) injection on day 1 (single treatment cycle)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. (in the muscle) injection on day 1 (single treatment cycle)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. (in the muscle) injection on day 1 (single treatment cycle)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: I.M. on day 1 (single treatment cycle)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.M. on day 1 (single treatment cycle)
Study: NCT00773292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclosporin
Description: Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
Study: NCT00468572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affectionate Writing
Description: Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaningless Writing
Description: Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
Study: NCT01857466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Floseal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar coagulation
Study: NCT03540147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hokanson Cuffs
Description: Each subject will participate in all (5) experimental arms. The order in which the experimental arms will be completed will be randomly assigned to the participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BStrong Bands
Description: Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BStrong Bands
Description: Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BStrong Bands
Description: Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BStrong Bands
Description: Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.
Study: NCT03959020

Intervention type: PROCEDURE
Intervention: Anti-reflux surgery
Description: Anti-reflux surgery for verified GERD
Study: NCT03415750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Conversion from Mycophenolate mofetil to Everolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Patients will remain in Tacrolimus + Mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study: NCT04396990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Prednisolone
Description: Standard of care topical drop treatment
Study: NCT01763190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral